dirkfrank Posted - 04/30/24

@justfacts1 if $WVE moves up shouldn’t $PRQR go up too

dirkfrank Posted - 04/30/24

$PRQR $WVE 👀??

dirkfrank Posted - 04/30/24

$WVE positive news and going down 😳💤

Stock_Titan Posted - 04/30/24

$WVE Wave Life Sciences Announces Approval of First Clinical Trial Application for RestorAATion-2 Trial of WVE-006 in Individuals with Alpha-1 Antitrypsin Deficiency (AATD) https://www.stocktitan.net/news/WVE/wave-life-sciences-announces-approval-of-first-clinical-trial-8g8k2wet81vy.html

dirkfrank Posted - 04/29/24

$SCPX how many RS? What’s $WVE link to this stock?

AllPlusLiving Posted - 04/29/24

$BMY $SCPX $WVE Time to fly 💝❤️‍🔥

Scooter0732 Posted - 04/26/24

$WVE getting tasty agajn

dirkfrank Posted - 04/25/24

@AllPlusLiving what’s the connection with $WVE ?

AllPlusLiving Posted - 04/23/24

$SCPX Remember Q1 2024: big news NightHawk’s Scorpius BioManufacturing Subsidiary Awarded Multimillion- Dollar Contract with a Publicly Traded Biotech Company to Support its Phase 2 Clinical Program… the Q1 2024 Report plus 2023 Year End report will be huge! $BMY $WVE Made in USA 🇺🇸

nastento Posted - 04/23/24

$WVE GSK continuation partnership. Loving it

valueforme Posted - 04/23/24

$WVE "As part of Wave’s ongoing collaboration with GSK, GSK has selected its first two programs to advance to development candidates following achievement of target validation. These programs utilize Wave’s next generation GalNAc-siRNA format and are in hepatology. GSK will provide an aggregate initiation payment of $12 million to Wave for these two oligonucleotide programs"

Stock_Titan Posted - 04/23/24

$WVE Wave Life Sciences Announces Continued Momentum in GSK Collaboration and Advancements in siRNA and RNA Editing https://www.stocktitan.net/news/WVE/wave-life-sciences-announces-continued-momentum-in-gsk-collaboration-g8l2phzu15yc.html

johnnygogogo Posted - 04/22/24

$PRQR what would be a reasonable, ie. very conservative royalty that ProQR could command from every competitor that successfully gets an ADAR-based drug across the finish line? 7%? 10%? 12%? All it will take is one competitor to belly up to the bar and strike a deal for price discovery (and precedent). Start adding up the enterprise value of its competitors $WVE $KRRO Shape (private), ADARx (private), etc.

dirkfrank Posted - 04/16/24

$WVE bought 5.30. Too soon?

dirkfrank Posted - 04/15/24

$WVE sold at 5.88.

dirkfrank Posted - 04/12/24

$WVE doesn’t like Iran rockets

valueforme Posted - 04/10/24

$WVE Surprisingly strong

dirkfrank Posted - 04/08/24

$WVE 2$ of the 52 wk high 😉

insiderbuyingselling Posted - 04/05/24

$WVE new insider selling: 15630 shares. http://insiderbuyingselling.com/?t=WVE

dirkfrank Posted - 04/05/24

$WVE back on 5.75. Who would have thought.

Stocks4thought Posted - 04/03/24

$WVE Dipper not a zipper...............nice catch.

bubbybubster Posted - 04/03/24

$WVE whale started dumping at 1:39 with a 50k block. was lucky to grab the bottom for a nice entry

bubbybubster Posted - 04/03/24

$WVE back to bottom of range and my price target to accumulate. got 10k shares at 5.75 to start

valueforme Posted - 04/03/24

I enjoyed how Maraganore trolled DNA editing folks today. siRNA / ADAR for the future $CDXS $WVE $PRQR https://twitter.com/JMaraganore/status/1775212882810020299?t=FXQAMkMWrzHB3K0RRQdilg&s=19

valueforme Posted - 04/02/24

No, GalNAc delivered editing oligos is the way to go in this case. No need for permanent or edits. $PRQR $WVE

waterlock Posted - 04/02/24

TOP 3 $MGTX $SANA $WVE typo

Stocks4thought Posted - 4 weeks ago

$WVE Breakfast Club------------- breaking for $7

valueforme Posted - 03/29/24

$WVE One of the reasons I invest in Wave is that they are trying to use the delivery approach that is proven by ALNY in their recent programs - GalNAc, not LNP. "Today, we have more than a decade of experience challenging convention related to oligonucleotide design and pioneering novel chemistry modifications to optimize the pharmacological properties of our molecules. We have seen preclinically and in clinical trials that these chemistry modifications enhance potency, distribution, and durability of effect of our molecules. Our novel chemistry also allows us to avoid using complex delivery vehicles, such as lipid nanoparticles and viruses, and instead use clinically proven conjugates (e.g. N-acetylgalactosamine or (“GalNAc”)) or free uptake for delivery to a variety of cell and tissue types. We maintain strong and broad intellectual property, including for our novel chemistry modifications. "

valueforme Posted - 03/29/24

Other notable holders of $PRQR (based on 2023 Q4 13-F): - EcoR1 Capital, LLC - 2,980,016 shares. Large bio-oriented fund. Bought in Q1 2023, likely after Lilly expanded their collaboration with PRQR - M28 Capital Management LP - 1,910,600. A way smaller bio oriented fund. Holding 1M shares since the original Lilly deal, doubled after the deal expansion. Very concentrated portfolio, just 10 holdings. Notable thing is that they own 6% of $WVE

Stocks4thought Posted - 03/28/24

$WVE $7 again $ALT fueling